Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

8.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.2K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.

Nature reviews. Urology·2026
Same author

Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer.

Cancer research·2026
Same author

Core competencies in prostate HDR brachytherapy: An American Brachytherapy Society Endorsed Competency Framework.

Brachytherapy·2026
Same author

Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer.

JNCI cancer spectrum·2026
Same author

Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer.

JCO precision oncology·2026
Same author

Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.

Cell reports. Medicine·2026

Related Experiment Video

Updated: Apr 29, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

High-risk prostate cancer-classification and therapy.

Albert J Chang1, Karen A Autio2, Mack Roach1

  • 1Department of Radiation Oncology, University of California, San Francisco, 1600 Divisadero Street, Suite H-1031, San Francisco, CA 94115, USA.

Nature Reviews. Clinical Oncology
|May 21, 2014
PubMed
Summary

High-risk prostate cancer definitions are too broad, impacting treatment. A better classification is needed for accurate identification and improved patient outcomes in prostate cancer management.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

19.4K

Related Experiment Videos

Last Updated: Apr 29, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

19.4K

Area of Science:

  • Oncology
  • Urology

Background:

  • High-risk prostate cancer affects approximately 15% of patients.
  • Current definitions encompass a heterogeneous patient group with varied prognoses.
  • Some high-risk cases progress to fatal disease, while others are curable with primary tumor treatment.

Purpose of the Study:

  • To critically evaluate the literature on defining and managing high-risk prostate cancer.
  • To highlight the need for a refined classification scheme for early and accurate identification.
  • To discuss evolving management strategies and unanswered questions in high-risk prostate cancer care.

Main Methods:

  • Review of existing clinical trial principles and literature.
  • Critical evaluation of current definitions and management approaches.
  • Identification of knowledge gaps and future research directions.

Main Results:

  • Current high-risk prostate cancer classifications are heterogeneous.
  • Optimal management for this subgroup is still evolving.
  • There is a need for improved diagnostic criteria to guide treatment decisions.

Conclusions:

  • A refined classification system is essential for precise identification of high-risk prostate cancer.
  • Accurate identification will facilitate the development of more effective treatment paradigms.
  • Further research is needed to optimize the care and outcomes for patients with high-risk prostate cancer.